We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App




Novel Adipokine Biomarker Reported for Insulin Resistance and Atherosclerosis

By LabMedica International staff writers
Posted on 21 Jul 2021
Print article
Image: The VITROS ECiQ Immunodiagnostic System (Photo courtesy of Ortho Clinical Diagnostics)
Image: The VITROS ECiQ Immunodiagnostic System (Photo courtesy of Ortho Clinical Diagnostics)
Diabetes Mellitus is a chronic condition occurring due to inadequate production or inadequate action of insulin, ultimately leading to hyperglycemia. Prediabetes, regarded as a precursor of diabetes, is a condition with elevated plasma glucose above normal levels, but below that of clinical disease.

Atherosclerotic cardiovascular diseases contribute to the world’s largest disease burden and are a leading cause of morbidity and mortality in both diabetics and prediabetics, accounting for about two third of mortality in diabetics. Increased levels of adipose derived cytokine (adipokine) apart from having immunological role, also have role in insulin resistant states and the process of atherosclerosis.

Medical Scientists at the Dr. Ram Manohar Lohia Hospital (New Delhi, India) included in a case control study 60 prediabetic patients and 60 age, sex, BMI matched controls. In both cases and controls serum levels of fasting and postprandial blood glucose, glycated hemoglobin (HbA1c) using a Vitros dry chemistry analyzer (Ortho Clinical Diagnostics, Bridgend, UK) and fasting insulin levels were measured by Chemiluminescence Immuno Assay (CLIA) on Vitros ECiQ. Homeostatic model assessment of insulin resistance (HOMA-IR) values in both the groups was calculated using fasting glucose and insulin levels. Serum Retinol Binding Protein-4 (RBP4) levels were measured using ELISA (IMMUNDIAGNOSTIK AG, Bensheim, Germany). The values obtained were compared between cases and controls. Carotid Intima-Media Thickness (CIMT) was only measured in cases using B-mode ultrasonography.

The investigators reported that the Median (IQR) of fasting plasma insulin levels (uIU/ml) in cases was 11.3 versus that of controls which was 5.73. HOMA-IR median (IQR) in cases and controls was 3.12 and 1.21 respectively. Median (IQR) for RBP4 in cases was 67.4 which were significantly higher as compared to controls 33.92. Significant positive correlation was seen between RBP4 with both, HOMA-IR and mean CIMT with correlation coefficients of 0.3693 and 0.621 respectively. On performing univariate linear regression analysis it was found that with increase in serum RBP4 levels by 1 mg/L, HOMA-IR and mean CIMT significantly increased by 0.007 units and 0.001 mm respectively.

The authors concluded prediabetics have been found to have more risk of cardiovascular events as compared to normoglycemics. Early assessment of the same with the use of novel biomarkers like RBP4 can be considered for early detection of atherosclerosis in prediabetic individuals. The study was published in the July 2021 issue of the Journal of the Association of Physicians of India.

Related Links:
Dr. Ram Manohar Lohia Hospital
Ortho Clinical Diagnostics
IMMUNDIAGNOSTIK AG


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.